ReviewCancers2018
Bladder Cancer: New Insights into Its Molecular Pathology.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04706598 (A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer), which is not on this map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer(NMIBC) Failing in BCG Treatment
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comparative Meta-Analysis andFrontiers in veterinary science · 2020Pooled it
- Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.Genome medicine · 2020Trial
- Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening.International journal of molecular sciences · 2026Article
- Utility of GATA3, Uroplakin-II, and p40 Markers in the Diagnosis of Urothelial Carcinoma.Cureus · 2026Article
- Genetic profiling and pathway analysis in bladder carcinoma: Implications for therapeutic targeting.Turkish journal of surgery · 2025Article
- Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models.BMC biotechnology · 2025Article
- Desmocollin-3 and Bladder Cancer.Diseases (Basel, Switzerland) · 2025Article
- STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer.Molecular and clinical oncology · 2025Article
- Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer.Frontiers in oncology · 2025Review
- Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.Frontiers in oncology · 2025Review
- Towards Reliable Methodology: Microbiome Analysis of Fresh Frozen vs. Formalin-Fixed Paraffin-Embedded Bladder Tissue Samples: A Feasibility Study.Microorganisms · 2024Article
- Mycobacteria Treatment Inhibits Bladder Cancer Cell Migration, Invasion, and Anchorage-Independent Growth.International journal of molecular sciences · 2024Article
- Article
- Association between CYP1A2 gene variants -163 C/A (rs762551) and -3860 G/A (rs2069514) and bladder cancer susceptibility.BMC cancer · 2024Article
- Fourteen years of cellular deconvolution: methodology, applications, technical evaluation and outstanding challenges.Nucleic acids research · 2024Review
- Mini-Review: Current Bladder Cancer Treatment-The Need for Improvement.International journal of molecular sciences · 2024Review
- Molecular Biomarkers of Bladder Cancer: A Mini-Review.Physiological research · 2023Review
- MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.Diagnostic pathology · 2023Article
- Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.Frontiers in oncology · 2023Article
- The biological impacts of CEBPD on urothelial carcinoma development and progression.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is one of the most prevalent cancers worldwide. Unfortunately, there have been few advances in its clinical management due to a poor understanding of the correlations between its molecular and clinical features. Mounting evidence suggests that bladder cancer comprises a group of molecularly heterogeneous diseases that undergo a variety of clinical courses and possess diverse therapeutic responses. Owing to the close association between its molecular subtypes and clinicopathological features, specific therapeutic strategies have recently been suggested. This review summarizes the current understanding of the molecular pathology of bladder cancer, including its molecular biomarkers/pathways and molecular subtypes that have been newly identified using high-throughput technologies. It also discusses advances in our understanding of personalized treatments for specific molecular subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.